Table 1. Expression of TADG-15 in relationship to age, clinical stage, histological type, and histological grade in patients with ovarian carcinomas.
| N | TADG-15 positive for expression (%) | P-valuea | |
|---|---|---|---|
| Ovarian carcinoma | 89 | 50 (56.2) | |
| Patient age (years) | 0.2776 | ||
| <50 | 40 | 25 (62.5) | |
| >51 | 49 | 25 (51.0) | |
| Clinical stage | 0.0157* | ||
| Stage I | 33 | 24 (72.7) | |
| Stage II/III/IV | 56 | 26 (46.4) | |
| Histological type | 0.0035* | ||
| Serous | 39 | 17 (43.6) | |
| Mucinous | 19 | 10 (52.6) | |
| Endometrioid | 17 | 9 (52.9) | |
| Clear cell | 14 | 14 (100) | |
| Histological grade | 0.2442 | ||
| Grade 1 | 54 | 33 (61.1) | |
| Grade 2/3 | 35 | 17 (48.6) |
a
χ2-test.
*
Statistically significant.